Prim. Univ.-Prof. Dr. Kurt HUBER
→Director, Wilhelminenspital, 3rd Med. Dept., Cardiology, Intensive Care Unit (ICU) and Chest Pain Unit (CPU)
know-how and research interests:
→Prof Huber is specialist in internal medicine, general and interventional cardiology and and intensive care medicine. His research interests include the pathophysiology, diagnosis, and treatment of ACS (UA, NSTEMI, STEMI); reperfusion strategies in STEMI, organization of STEMI networks; antithrombotic therapy in atrial fibrillation; biomarkers in ACS and atrial fibrillation; mechanisms of restenosis and stent thrombosis; the plasmin activation system in disease; anticoagulation and antiplatelet therapy in cardiovascular diseases; the role of platelet function testing; statins; heart failure and diabetes in heart.
research topics (general title):
Biomarkers in Cardiovascular Diseases (in cooperation with the Ludwig Boltzmann Cluster of Cardiovascular Disease at the Medical University in Vienna)
Acute Coronary Syndromes. Organization and Antitrhombotic Therapy
techniques and infrastructure of the research group:
→The group has access to all important basic research facilities known important for biovascular research
5 selected publications:
Jäger B, Farhan S, Rohla M, Christ G, Podczeck-Schweighofer A, Schreiber W, Laggner AN, Weidinger F, Stefenelli T, Delle-Karth G, Kaff A, Maurer G, Huber K ; Vienna STEMI Registry Group. Clinical predictors of patient related delay in the VIENNA ST-elevation myocardial infarction network and impact on long-term mortality. Eur Heart J Acute Cardiovasc Care. 2016 Feb 17. pii: 2048872616633882. [Epub ahead of print].
Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe AS, Möckel M, Giannitsis E, Thygesen K, Ten Berg JM, Mueller C, Storey RF, Lindahl B, Huber K; on behalf of the Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology and the Working Group on Thrombosis of the European Society of Cardiology. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost. 2015 Jan 27;113(2):221-30.
Huber K. Prasugrel in Clopidogrel Nonresponders: A Way to Improve Secondary Prevention in Patients After Percutaneous Coronary Intervention? JACC Cardiovasc Interv. 2015 Oct;8(12):1571-3.
Huber K, Gersh BJ, Goldstein P, Granger CB, Armstrong PW. The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. Eur Heart J. 2014 Jun 14;35(23):1526-32.
Demyanets S, Tentzeris I, Jarai R, Katsaros KM, Farhan S, Wonnerth A, Weiss TW, Wojta J, Speidl WS, Huber K. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine. 2014 Jun;67(2):65-70.